Tag Archives: Janet Woodcock

Woodcock Urges Forward March Toward Personalized Medicine

New approaches for conducting clinical trials and developing therapies that actually prevent and cure disease are key to the future of effective drug therapy, according to Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). Personalized medicine has achieved mainstream status, accounting for more new drug approvals and promising pipeline candidates, […]
Posted in Technology | Also tagged , , , , , , , , , , | Leave a comment

PCORI Launches Clinical Research Network to Support Trials, Outcomes Research

The new National Patient-Centered Clinical Research Network funded by the Patient-Centered Outcomes Research Institute (PCORI) aims to provide patients and clinicians with useful information on treatment options and outcomes. By encouraging more comparative clinical effectiveness research (CER),  the program also has potential to support development of new drugs and devices, explained PCORI executive director Joe […]
Posted in FDA, healthcare | Also tagged , , , , , , , , , , , , , | Leave a comment

CDER Runs into Trouble with Generic Drug Reorg Plan

After less than a year on the job, the head of FDA’s Office of Generic Drugs (OGD) has announced his departure, a sign that all is not well with plans for major organizational changes at the Center for Drug Evaluation and Research (CDER).
Posted in FDA, leadership, Legal | Also tagged , , , , , , , , | Leave a comment

Following Industry, OPDP Hopes to Eliminate Silos in Ad Review

The Office of Prescription Drug Promotion (OPDP) is reorganizing its two primary advertising review divisions – professional and consumer – in an attempt to stay in line with the silo-breaking, multi-channel promotional output pouring in from pharma. The line between physician marketing and consumer marketing has blurred as the facets of a brand campaign – […]
Posted in Advertising, compliance, E-Media, FDA, Legal, Marketing, Patient Communication, patient education, Regulatory, Sales, social media | Also tagged , , | Leave a comment

Highlights from the Leerink Swann Healthcare Conference

Over a hundred public companies, dozens of clinicians, and several regulators participated in investment firm Leerink Swann’s 2012 Healthcare Conference in mid-February. Press was barred from the event, but John Sullivan, Leerink’s director of research, gives PharmExec a few of the take-aways.
Posted in Biotech, Events, FDA, Gene therapy, leadership, Strategy, Technology | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta